Published in Psychopharmacology (Berl) on June 16, 2004
Identifying profiles of recovery from reward devaluation in rats. Behav Brain Res (2014) 0.77
Validation of open:closed arm entries in an elevated plus-maze as a measure of anxiety in the rat. J Neurosci Methods (1985) 9.05
The endogenous cannabinoid system controls extinction of aversive memories. Nature (2002) 7.19
Cannabinoid receptor localization in brain. Proc Natl Acad Sci U S A (1990) 5.48
A review of 25 years of the social interaction test. Eur J Pharmacol (2003) 2.74
Cannabinoid receptors in the human brain: a detailed anatomical and quantitative autoradiographic study in the fetal, neonatal and adult human brain. Neuroscience (1997) 2.56
Can social interaction be used to measure anxiety? Br J Pharmacol (1978) 2.50
The use of social interaction as a method for detecting anxiolytic activity of chlordiazepoxide-like drugs. J Neurosci Methods (1980) 2.26
Anandamide induces overeating: mediation by central cannabinoid (CB1) receptors. Psychopharmacology (Berl) (1999) 2.17
Distribution of CB1 cannabinoid receptors in the amygdala and their role in the control of GABAergic transmission. J Neurosci (2001) 2.15
Contrasted conditions of reinforcement. A selective critique. Psychol Bull (1968) 1.42
The influence of open arm ledges and maze experience in the elevated plus-maze. Pharmacol Biochem Behav (1996) 1.39
Bimodal modulation by nicotine of anxiety in the social interaction test: role of the dorsal hippocampus. Behav Neurosci (1998) 1.26
Cannabinoid influences on palatability: microstructural analysis of sucrose drinking after delta(9)-tetrahydrocannabinol, anandamide, 2-arachidonoyl glycerol and SR141716. Psychopharmacology (Berl) (2002) 1.15
Pharmacological characterization of cannabinoids in the elevated plus maze. J Pharmacol Exp Ther (1990) 1.13
Corticotropin-releasing factor has an anxiogenic action in the social interaction test. Horm Behav (1987) 1.11
Cannabinoid effects on anxiety-related behaviours and hypothalamic neurotransmitters. Pharmacol Biochem Behav (2001) 1.10
Time-course of changes in the social interaction test of anxiety following acute and chronic administration of nicotine. Behav Pharmacol (1999) 1.00
The dorsal raphé nucleus is a crucial structure mediating nicotine's anxiolytic effects and the development of tolerance and withdrawal responses. Psychopharmacology (Berl) (2001) 0.99
Dissociation between behavioral and corticosterone responses on repeated exposures to cat odor. Physiol Behav (1993) 0.96
Involvement of the kappa-opioid receptor in the anxiogenic-like effect of CP 55,940 in male rats. Pharmacol Biochem Behav (2003) 0.94
Age-associated sex differences in response to food deprivation in two animal tests of anxiety. Neurosci Biobehav Rev (2003) 0.93
Temporal dynamics of corticosterone elevation in successive negative contrast. Physiol Behav (1998) 0.89
Chlordiazepoxide reduces the generalised anxiety, but not the direct responses, of rats exposed to cat odor. Pharmacol Biochem Behav (1992) 0.87
Low but not high doses of buspirone reduce the anxiogenic effects of diazepam withdrawal. Psychopharmacology (Berl) (1991) 0.81
Medial and lateral amygdalectomy differentially influences consummatory negative contrast. Physiol Behav (1984) 0.80
Anxiety conditioned to nicotine in the elevated plus-maze is time dependent. Behav Pharmacol (2002) 0.79
Anxiogenic effects in benzodiazepine withdrawal are linked to the development of tolerance. Brain Res Bull (1987) 0.79
Incentive downshifts evoke search repertoires in rats. J Exp Psychol Anim Behav Process (1999) 0.79
Conditions under which chlordiazepoxide influences gustatory contrast. Psychopharmacology (Berl) (1980) 0.78
Effect of serotonergic drugs on negative contrast in consummatory behavior. Pharmacol Biochem Behav (1990) 0.78
Chlordiazepoxide and the moderation of the initial response to reward reduction. Q J Exp Psychol B (1990) 0.78
The effects of morphine in the consummatory contrast paradigm. Psychopharmacology (Berl) (1987) 0.78
Chlordiazepoxide and ethanol additively reduce gustatory negative contrast. Psychopharmacology (Berl) (1983) 0.78
Influence of ethanol on contrast in consummatory behavior. Psychopharmacology (Berl) (1982) 0.78
Habituation and generalization of phobic responses to cat odor. Brain Res Bull (1994) 0.78
Cyproheptadine prevents the initial occurrence of successive negative contrast. Pharmacol Biochem Behav (1991) 0.77
Comparison of the effects of the benzodiazepine midazolam and three serotonin antagonists on a consummatory conflict paradigm. Pharmacol Biochem Behav (1986) 0.76
Amobarbital sodium reduces successive gustatory contrast. Psychopharmacology (Berl) (1980) 0.75
Validation of open:closed arm entries in an elevated plus-maze as a measure of anxiety in the rat. J Neurosci Methods (1985) 9.05
Effect of dapagliflozin in patients with type 2 diabetes who have inadequate glycaemic control with glimepiride: a randomized, 24-week, double-blind, placebo-controlled trial. Diabetes Obes Metab (2011) 2.77
Anxiolytic and anxiogenic drug effects on exploratory activity in an elevated plus-maze: a novel test of anxiety in the rat. Pharmacol Biochem Behav (1986) 2.73
Effects of moderate alcohol consumption on the central nervous system. Alcohol Clin Exp Res (1998) 2.60
Can social interaction be used to measure anxiety? Br J Pharmacol (1978) 2.50
Validity of head-dipping as a measure of exploration in a modified hole-board. Psychopharmacologia (1975) 2.46
The use of social interaction as a method for detecting anxiolytic activity of chlordiazepoxide-like drugs. J Neurosci Methods (1980) 2.26
Effects of hospital-acquired conditions on length of stay for patients with diabetes. Intern Med J (2014) 1.99
Population pharmacokinetics and pharmacodynamics of piperaquine in children with uncomplicated falciparum malaria. Clin Pharmacol Ther (2012) 1.87
Sex differences in animal tests of anxiety. Physiol Behav (1991) 1.74
Structural basis and mechanism of enoyl reductase inhibition by triclosan. J Mol Biol (1999) 1.67
The shoulder abduction relief sign in cervical radiculopathy. Arch Phys Med Rehabil (1989) 1.60
Dapagliflozin maintains glycaemic control while reducing weight and body fat mass over 2 years in patients with type 2 diabetes mellitus inadequately controlled on metformin. Diabetes Obes Metab (2013) 1.54
Dapagliflozin in patients with type 2 diabetes receiving high doses of insulin: efficacy and safety over 2 years. Diabetes Obes Metab (2013) 1.50
Night backache in pregnancy. Hypothetical pathophysiological mechanisms. Am J Phys Med Rehabil (1989) 1.42
The American Brachytherapy Society recommendations for high-dose-rate brachytherapy for carcinoma of the endometrium. Int J Radiat Oncol Biol Phys (2000) 1.41
The influence of open arm ledges and maze experience in the elevated plus-maze. Pharmacol Biochem Behav (1996) 1.39
Dapagliflozin has no effect on markers of bone formation and resorption or bone mineral density in patients with inadequately controlled type 2 diabetes mellitus on metformin. Diabetes Obes Metab (2012) 1.37
Re-activation of a dormant tumor suppressor gene maspin by designed transcription factors. Oncogene (2006) 1.35
Specific motifs in the external loops of connexin proteins can determine gap junction formation between chick heart myocytes. J Physiol (1995) 1.29
Efficacy and safety of dapagliflozin as a monotherapy for type 2 diabetes mellitus in Japanese patients with inadequate glycaemic control: a phase II multicentre, randomized, double-blind, placebo-controlled trial. Diabetes Obes Metab (2013) 1.28
Factor analysis shows that female rat behaviour is characterized primarily by activity, male rats are driven by sex and anxiety. Pharmacol Biochem Behav (1999) 1.26
5-HT1A and benzodiazepine receptors in the basolateral amygdala modulate anxiety in the social interaction test, but not in the elevated plus-maze. Brain Res (1996) 1.25
Do lorazeam-induced deficits in learning result from impaired rehearsal, reduced motivation or increased sedation? Br J Clin Pharmacol (1982) 1.20
Intraocular cilia associated with perforating injury. Indian J Ophthalmol (2000) 1.18
Nicotine self-administration and withdrawal: modulation of anxiety in the social interaction test in rats. Psychopharmacology (Berl) (2001) 1.13
The reliability of the hole-board apparatus. Psychopharmacologia (1975) 1.11
Corticotropin-releasing factor has an anxiogenic action in the social interaction test. Horm Behav (1987) 1.11
Endogenous cell seeding. Remnant endothelium after stenting enhances vascular repair. Circulation (1996) 1.10
Effects of ethanol and chlordiazepoxide on social interaction in rats [proceedings]. Br J Pharmacol (1976) 1.10
Review article: reflux and its consequences--the laryngeal, pulmonary and oesophageal manifestations. Conference held in conjunction with the 9th International Symposium on Human Pepsin (ISHP) Kingston-upon-Hull, UK, 21-23 April 2010. Aliment Pharmacol Ther (2011) 1.10
Studies on the role of ACTH and of 5-HT in anxiety, using an animal model. J Pharm Pharmacol (1978) 1.10
Evidence for a complex influence of nicotinic acetylcholine receptors on hippocampal serotonin release. J Neurochem (2000) 1.08
Behavioral consequences in animal tests of anxiety and exploration of exposure to cat odor. Brain Res Bull (1992) 1.07
Handling history of rats modifies behavioural effects of drugs in the elevated plus-maze test of anxiety. Eur J Pharmacol (1993) 1.07
Impaired performance and sedation after a single dose of lorazepam. Psychopharmacology (Berl) (1979) 1.03
Incidental lymphocytic prostatitis. Selective involvement with nonmalignant glands. Am J Surg Pathol (1992) 1.03
Evidence that the median raphé nucleus--dorsal hippocampal pathway mediates diazepam withdrawal-induced anxiety. Psychopharmacology (Berl) (1997) 1.03
Limited genetic susceptibility to severe Graves' ophthalmopathy: no role for CTLA-4 but evidence for an environmental etiology. Thyroid (2000) 1.01
Time-course of changes in the social interaction test of anxiety following acute and chronic administration of nicotine. Behav Pharmacol (1999) 1.00
Tolerance to nicotine's effects in the elevated plus-maze and increased anxiety during withdrawal. Pharmacol Biochem Behav (2001) 1.00
The dorsal raphé nucleus is a crucial structure mediating nicotine's anxiolytic effects and the development of tolerance and withdrawal responses. Psychopharmacology (Berl) (2001) 0.99
Intrinsic actions of the benzodiazepine receptor antagonist Ro 15-1788. Psychopharmacology (Berl) (1986) 0.98
Involvement of 5-HT1A receptors in behavioural effects of the cannabinoid receptor agonist CP 55,940 in male rats. Behav Pharmacol (2004) 0.98
Antagonistic effects of caffeine and yohimbine in animal tests of anxiety. Eur J Pharmacol (1989) 0.97
Formation and implications of a ternary complex of profilin, thymosin beta 4, and actin. J Biol Chem (2001) 0.97
The effects of triazolobenzodiazepines in two animal tests of anxiety and in the holeboard. Br J Pharmacol (1985) 0.97
Interaction between effects of caffeine and lorazepam in performance tests and self-ratings. J Clin Psychopharmacol (1982) 0.97
Drug-induced asthma: a review. Ann Allergy (1980) 0.96
Multiple sites of action for anxiogenic drugs: behavioural, electrophysiological and biochemical correlations. Psychopharmacology (Berl) (1984) 0.95
Isolated posterior capsule rupture in blunt trauma: pathogenesis and management. Ophthalmic Surg Lasers (1998) 0.95
Acute nicotine decreases, and chronic nicotine increases the expression of brain-derived neurotrophic factor mRNA in rat hippocampus. Brain Res Mol Brain Res (2000) 0.95
Yohimbine's anxiogenic action: evidence for noradrenergic and dopaminergic sites. Pharmacol Biochem Behav (1989) 0.95
Current therapy in the management of heterotopic ossification of the elbow: a review with case studies. Am J Phys Med Rehabil (1999) 0.95
Medial prefrontal transection enhances social interaction. I: behavioral studies. Brain Res (2000) 0.95
Echinococcal infestation of the spine in North America. Clin Orthop Relat Res (1991) 0.94
Accommodating planned exercise in type I diabetic patients on intensive treatment. Diabetes Care (1985) 0.94
Corticosterone -- an anxiogenic or an anxiolytic agent? J Pharm Pharmacol (1979) 0.94
Modulation of behaviour on trials 1 and 2 in the elevated plus-maze test of anxiety after systemic and hippocampal administration of nicotine. Psychopharmacology (Berl) (1999) 0.94
Stimulation of benzodiazepine receptors in the dorsal hippocampus and median raphé reveals differential GABAergic control in two animal tests of anxiety. Eur J Neurosci (1998) 0.94
Giant cell tumour of bone. A surgical approach to grade III tumours. Int Orthop (1993) 0.94
The anxiogenic action of benzodiazepine antagonists. Neuropharmacology (1982) 0.94
Aversive and appetitive properties of anxiogenic and anxiolytic agents. Behav Brain Res (1986) 0.93
Selectively bred lines of rats differ in social interaction and hippocampal 5-HT1A receptor function: a link between anxiety and depression? Pharmacol Biochem Behav (1998) 0.93
Long-term glycaemic response and tolerability of dapagliflozin versus a sulphonylurea as add-on therapy to metformin in patients with type 2 diabetes: 4-year data. Diabetes Obes Metab (2015) 0.93
Sedative effects of PK 9084 and PK 8165, alone and in combination with chlordiazepoxide. Br J Pharmacol (1983) 0.93
Magnetic resonance imaging of the paranasal sinuses: incidental abnormalities and their relationship to patient symptoms. J Otolaryngol (2001) 0.93
Do the reductions in social interaction produced by picrotoxin and pentylenetetrazole indicate anxiogenic actions? Neuropharmacology (1984) 0.92
Methodological considerations in neurobehavioral teratology. Pharmacol Biochem Behav (1996) 0.92
Mice lacking the cell adhesion molecule Thy-1 fail to use socially transmitted cues to direct their choice of food. Curr Biol (2000) 0.92
Effects of two anxiolytics on distraction, habituation and dishabitiuation. Pharmacol Biochem Behav (1977) 0.91
Vitreoschisis in Eales' disease: pathogenic role and significance in surgery. Retina (1999) 0.91
5-HT1A receptors in the median raphe nucleus and dorsal hippocampus may mediate anxiolytic and anxiogenic behaviours respectively. Eur J Pharmacol (1994) 0.91
Functional lymphatic alterations in patients suffering from lipedema. Angiology (1995) 0.91
Decreased 5-HT1A and increased 5-HT2A receptor binding after chronic corticosterone associated with a behavioural indication of depression but not anxiety. Psychoneuroendocrinology (1997) 0.91
High intracellular calcium concentrations in transformed lymphoblasts from subjects with bipolar I disorder. Am J Psychiatry (1997) 0.91
Tolerance to the anti-pentylenetetrazole effects of diazepam in the mouse. Psychopharmacology (Berl) (1983) 0.90
Pharmacokinetic studies on Ro 15-1788, a benzodiazepine receptor ligand, in the brain of the rat. Brain Res (1984) 0.90
Regional differences in rat benzodiazepine binding in response to novelty and cat odour. Neuropharmacology (1994) 0.90
Selective agonists and antagonists for 5-hydroxytryptamine receptor subtypes, and interactions with yohimbine and FG 7142 using the elevated plus-maze test in the rat. J Pharm Pharmacol (1987) 0.90
The effects of piracetam on acquisition and retention of habituation [proceedings]. Br J Pharmacol (1977) 0.90
Endophthalmitis caused by anaerobic bacteria. Indian J Ophthalmol (1995) 0.90
On the convulsant action of Ro 5-4864 and the existence of a micromolar benzodiazepine binding site in rat brain. Psychopharmacology (Berl) (1984) 0.90
The effect of treatment regimen on the development of tolerance to the sedative and anxiolytic effects of diazepam. Psychopharmacology (Berl) (1999) 0.89
Rabies post-exposure prophylaxis in malnourished children exposed to suspect rabid animals. Vaccine (2005) 0.89
A test of anxiety that distinguishes between the actions of benzodiazepines and those of other minor tranquilisers and of stimulants. Pharmacol Biochem Behav (1979) 0.89
A five minute experience in the elevated plus-maze alters the state of the benzodiazepine receptor in the dorsal raphe nucleus. J Neurosci (1997) 0.89
Antagonism of the anxiolytic effect of nicotine in the dorsal raphe nucleus by dihydro-beta-erythroidine. Pharmacol Biochem Behav (2001) 0.89
Nicotine regulates 5-HT(1A) receptor gene expression in the cerebral cortex and dorsal hippocampus. Eur J Neurosci (2001) 0.89
Glutamate release in the nucleus accumbens is involved in behavioral depression during the PORSOLT swim test. Neuroscience (2003) 0.89
Acute and chronic effects of three benzodiazepines in the social interaction anxiety test in mice. Psychopharmacology (Berl) (1979) 0.88
Role of the neutrophil in abdominal aortic aneurysm development. Cardiovasc Surg (1993) 0.88
Extracellular glutamate increases in the lateral hypothalamus and decreases in the nucleus accumbens during feeding. Brain Res (1997) 0.88
Methyllycaconitine (MLA) blocks the nicotine evoked anxiogenic effect and 5-HT release in the dorsal hippocampus: possible role of alpha7 receptors. Neuropharmacology (2003) 0.88
Tolerance to the behavioral actions of benzodiazepines. Neurosci Biobehav Rev (1985) 0.88
Retinal detachment secondary to ocular perforation during retrobulbar anaesthesia. Indian J Ophthalmol (1995) 0.88
Rapid development of tolerance to the sedative effects of lorazepam and triazolam in rats. Psychopharmacology (Berl) (1981) 0.88
Changing the transition state for protein (Un) folding. Biochemistry (1996) 0.88
Animal models for predicting clinical efficacy of anxiolytic drugs: social behaviour. Neuropsychobiology (1985) 0.88